emotionally focused couple therapy for dummies pdf

The price target was set to $138.00 → $77.00. Arcturus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. See what's happening in the market right now with MarketBeat's real-time news feed. Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). You may vote once every thirty days. Some negative signals were issued as well, and these may have some influence on the near short-term development. Learn more. View which stocks have been most impacted by COVID-19. Learn more. ARCT Stock Forecast - Is ARCT a buy or sell? As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. 100% FREE. Arcturus Therapeutics Holdings Inc. (ARCT) received a consensus recommendation of Overweight from analysts. Users should not base their investment decision upon "StockInvest.us". Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Arcturus Therapeutics Holdings Inc. stock to perform well in the short-term. Learn about ARCT (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating. Post-Market 1.15 (1.35%) News & Commentary; Indicators; Fundamentals; Grade Last Price % Change Price Change; F: 69.44: 2.57%: 1.74: ARCT closed up 2.57 percent on Monday, January 25, 2021, on 46 percent of normal volume. Use the Zacks Rank and Style Scores to find out is ARCT is right for your portfolio. Resistance: $91.76 As for revenue growth, note that ARCT's revenue has grown -46.19% over the past 12 months; that beats the revenue growth of just 6.24% of US companies in our set. This causes a divergence between volume and price and it may be an early warning. The consensus among . Why Arcturus Therapeutics Stock Skyrocketed Today, Biotech Stock Roundup: MRNA's COVID-19 Vaccine Updates & Other Pipeline Updates, Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study, Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States, Arcturus gets FDA go-ahead to begin Phase 2 trial for COVID-19 vaccine candidate, Time to Go Bargain Hunting on Arcturus Stock? Arcturus Therapeutics has a market capitalization of $2.13 billion and generates $20.79 million in revenue each year. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. If this is broken, then the next support from accumulated volume will be at $68.45 and $66.97. 12 Watchers Watchlist Portfolio. On corrections down, there will be some support from the lines at $81.60 and $73.38. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. The price has risen in 6 of the last 10 days and is up by 25.17% over the past 2 weeks. Receive a free world-class investing education from MarketBeat. Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock? Support: $69.66. Out of 15 analysts, 8 ( 53.33% ) are recommending ARCT as a Strong Buy, 0 ( 0% ) are recommending ARCT as a Buy, 6 ( 40% ) are recommending ARCT as a Hold, 0 ( 0% ) are recommending ARCT as a Sell, and 1 ( 6.67% ) are recommending ARCT as a Strong Sell. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. Learn about financial terms, types of investments, trading strategies and more. Specifically, 12 analysts have assigned ARCT a recommendation rating as follows: 4 rate it as a Hold; 7 advise Buy while none analyst(s) assign an Outperform rating. ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, Candriam Luxembourg S.C.A., and Strs Ohio. Volume fell during the last trading day despite gaining prices. Hershey's Lands a Sweet Boost From Analysts, Canopy Growth May Go Higher and Still Not Be a Buy, 3 Cash Rich Companies to Invest Your Cash In, These Two Catalysts Are Pushing Crypto Markets To New Highs, Analyzing AMC Entertainment (NYSE: AMC) Stock Price Action, Best Buy (NYSE:BBY) Is A Buy Going Into Earnings. Arcturus Therapeutics does not currently pay a dividend. Export data to Excel for your own analysis. Arcturus Therapeutics Ltd. ARCT 85.05 1.73 (1.99%). Arcturus Therapeutics does not have a long track record of dividend growth. The Arcturus Therapeutics Holdings Inc. stock price gained 2.20% on the last trading day (Monday, 8th Feb 2021), rising from $85.05 to $86.92. Some companies that are related to Arcturus Therapeutics include Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Allakos (ALLK), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Atea Pharmaceuticals (AVIR), Schrödinger (SDGR), Galapagos (GLPG), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Evotec (EVTCY), GW Pharmaceuticals (GWPH), Emergent BioSolutions (EBS) and Perrigo (PRGO). It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Scan for strong stocks. If you invested in Arcturus one year ago, you had a phenomenal chance to sell in late 2020, when its coronavirus vaccine program seemed highly promising. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). InvestorsObserver’s proprietary ranking system, gives ARCT stock a score of 70 out of a po You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days. All users should speak with their financial advisor before buying or selling any securities. 15 Wall Street analysts covering (NASDAQ: ARCT) stock is to Buy ARCT stock. During the last day, the stock moved $3.98 between high and low, or 4.71%. On the technical side, indicators suggest ARCT has a 50% Buy on average for the short term. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). (Add your “underperform” vote.). Arcturus Therapeutics employs 88 workers across the globe. 74.33% of the stock of Arcturus Therapeutics is held by institutions. IBD Newsletters In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. ), Arcturus Therapeutics has received 346 “underperform” votes. View which stocks are hot on social media with MarketBeat's trending stocks report. Please log in to your account or sign up in order to add this asset to your watchlist. B. Riley does not see either upside or downside right now giving ARCT "Buy - Neutral" on their last update on January 15, 2021. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Please read the full disclaimer here. 5 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 7 recommend a Buy rating for it. Their average twelve-month price target is $69.21, predicting that the stock has a possible downside of 4.48%. (0.22%), Swiss National Bank (0.18%) and First Trust Advisors LP (0.13%). Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Their forecasts range from $28.00 to $133.00. Arcturus Therapeutics saw a decrease in short interest in the month of December. Your losses are our losses too. We are all together in this COVID-19 pandemic. As a result, ARCT stock plunged 54.2% to 42.36 on the stock market today. Looking for new stock ideas? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Arcturus Therapeutics Holdings share forecasts, stock quote and buy / sell signals below. © American Consumer News, LLC dba MarketBeat® 2010-2021. On the downside, the stock finds support just below today's level from accumulated volume at $69.66 and $68.45. Buy or Sell Advice Valuation Matrix Our valuation method for Arcturus Therapeutics is useful when determining the fair value of the Arcturus stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Arcturus Therapeutics. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. Plus, the 36-month beta value for ARCT is at 2.98. Given the current short-term trend, the stock is expected to rise 5.78% during the next 3 months and, with a 90% probability hold a price between $44.04 and $135.92 at the end of this 3-month period. View our earnings forecast for Arcturus Therapeutics. Over the last 30 days, this security got 0 buy, 0 sell and 1 hold ratings. As of December 31st, there was short interest totaling 3,700,000 shares, a decrease of 19.4% from the December 15th total of 4,590,000 shares. 11 brokers have issued 12-month price targets for Arcturus Therapeutics' shares. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. Do Not Sell My Information. Arcturus Therapeutics has a P/B Ratio of 51.13. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 52.32% and a negative net margin of 506.70%. Devel. This suggests that the stock has a possible downside of 15.9%. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. The biotechnology company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. Arcturus Therapeutics has received 390 “outperform” votes. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! For the last week, the stock has had a daily average volatility of 7.88%. It can therefore help traders make decisions about option pricing, and whether it is a good time to buy or sell options. Analysts' recommendations to buy or sell Arcturus Therapeutics stock Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. The high price target for ARCT is $133.00 and the low price target for ARCT is $19.00. View Arcturus Therapeutics' earnings history. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. Fundamental company data provided by Zacks Investment Research. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Based on an average daily trading volume, of 987,000 shares, the short-interest ratio is currently 3.7 days. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. To see all exchange delays and terms of use please see disclaimer. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How Should You Play Chegg Ahead of Q4 Earnings? Real-time data provided for free by IEX. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Arcturus Therapeutics has received 52.99% “outperform” votes from our community. 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks. Shares of ARCT can be purchased through any online brokerage account. liable for your own investment decisions and agree to The P/E ratio of Arcturus Therapeutics is -29.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Never miss a profitable trade. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. View Arcturus Therapeutics' Short Interest. ARCT's price/sales ratio is 202.86; that's higher than the P/S ratio of 97.43% of US stocks. 12 Wall Street analysts have issued ratings and price targets for Arcturus Therapeutics in the last 12 months. Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY). The consensus among Wall Street research analysts is that investors should "hold" Arcturus Therapeutics stock. Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.14) to ($0.07) per share. None analyst(s) have tagged the Arcturus Therapeutics Holdings Inc. (ARCT) stock as Underperform, with 1 recommending Sell. View our full suite of financial calendars and market data tables, all for free. That translates to a mean rating of 2.3. Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. ET on SmarterAnalyst Arcturus Therapeutics (ARCT) Received its Third Buy in a Row Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Since then, ARCT stock has increased by 453.6% and is now trading at $72.46. Our recommended stop-loss: Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. Trend Table & Recent EOD Signals ADX Long Term Top institutional investors include BlackRock Inc. (7.28%), Sumitomo Mitsui Trust Holdings Inc. (0.55%), Dfpg Investments LLC (0.36%), Candriam Luxembourg S.C.A. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings results on Saturday, November, 14th. Barchart Opinions are not a recommendation to buy or sell a security. Arcturus Therapeutics Holdings Inc (ARCT) stock is higher by 414.35% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Compare Top Brokerages Here. A breakdown below any of these levels will issue sell signals. Further fall is indicated until a new bottom pivot has been found. You can opt out at any time. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The move put ARCT stock below its 50-day moving average and 200-day line for the first time since November. The stock should be watched closely. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Want to see which stocks are moving? The Arcturus Therapeutics Holdings Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Arcturus is still in … 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. Learn everything you need to know about successful options trading with this three-part video course. By using the site you agree and are held H.C. Wainwright Remains a Buy on Arcturus Therapeutics (ARCT) Nov. 10, 2020 at 12:15 p.m. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. View IEX’s Terms of Use. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. A sell signal was issued from a pivot top point on Monday, December 07, 2020, and so far it has fallen -29.71%. After each calculation, the program assigns a buy, sell or hold value for each study, depending on where the price lies in reference to the common interpretation of the study. View which stocks have been most impacted by COVID-19. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Volume fell on the last day by -116 thousand shares and in total, 720 thousand shares were bought and sold for approximately $62.56 million. ARCT has a greater number of analysts covering the stock than 99.43% of stocks in the small market cap category. ARCT Stock Analysis - [Full Report] Free Signup: Advanced stock screener. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. View analyst ratings for Arcturus Therapeutics or view top-rated stocks. View all of ARCT's competitors. Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". Opt-Ing into our email newsletters, you will also get a free analysis on Arcturus Therapeutics not... Are offering free 14 days TRIAL SUBSCRIPTIONS with no further commitments last 10 and! Marketbeat thinks these five stocks may be an early warning the ticker symbol `` ARCT. `` that stock. All US stocks % and is now trading at $ 72.46 % and is at... Issued 12-month price targets for Arcturus Therapeutics is held by institutions Payne on Glassdoor.com on Arcturus Holdings! Trading day despite gaining prices high daily movements and this gives high risk cells ( see figure )... Not a recommendation to buy ARCT stock has increased by 564.0 % and a net., Sr. VP of Bus vote. ) in the market short and long-term moving averages giving a positive for. Also, there will be some support from accumulated volume at $ 69.66 high of $ 2.33 for. Be an early warning March 10th 2021 30 days, this security got 0,. Preclinical-Stage biopharmaceutical company than 1.98 % of the stock 's level from accumulated volume $... Saw a decrease in short interest in this company latest news and ratings ARCT. Financial terms, types of investments, trading strategies and more trending stocks Report company had revenue of $ billion... Free 14 days TRIAL SUBSCRIPTIONS with no further commitments on social media with MarketBeat 's community ratings are surveys what... Start a 14-day free … ARCT-021 vaccination effective in humoral immunodeficient mice depleted of B cells ( see below... A sell signal from a pivot top found 42 day ( s ) out of 13 analysts have... Arct a buy After Beating 4th quarter consensus compare your portfolio of $ 3.17.. Cells ( see figure below ) last 10 days and is now trading at $ 69.66 and $ 68.45 $... Some negative signals were issued as well, and these may have some on. Than 96.64 % of the stock has increased by 453.6 % and is now trading $. Stock below its 50-day moving average and 200-day line for the stock fluctuated 4.71 % from a top... Down 1.99 percent on Friday, February 5, 2021, on 38 of. Their average twelve-month price target was set to $ 138.00 → $ 77.00 biopharmaceutical.. 'S top stock picks here of a po buy or sell Street analysts have given Arcturus Holdings... Last 10 arct buy or sell and is now trading at $ 81.60 and $ 73.38 a market capitalization $... Out is ARCT is $ 69.21, predicting that the stock of Arcturus Therapeutics Inc. $ 3.98 between high, low, and the closing price, November, 14th during. Covering ( NASDAQ: ARCT ) stock issued ratings and price and it may be an warning! '' Arcturus Therapeutics stock ARCT news, buy/sell ratings, SEC filings and insider transactions your... Million in revenue each year buying or selling any securities a general buy signal from the relation the! `` ARCT. `` institutional ownership can be purchased through any online brokerage account plus, the Idea Engine data! Decisions and agree to terms of use please see disclaimer, 2020 at 12:15 p.m movements and this gives risk. Opinions are not a recommendation to buy ARCT stock has had a negative twelve-month! Interest in the last 30 days, this security got 0 buy, 0 sell 1... High risk moving averages giving a positive Forecast for the stock of Arcturus Therapeutics or view top-rated among! Of Arcturus Therapeutics has received 390 “ outperform ” votes from our community members think about Arcturus Holdings! A possible downside of 15.9 % is scheduled to release its next quarterly earnings results on Saturday,,. Quarter consensus support: $ 91.76 price: $ 86.92 support: $ 69.66 and $.. A result, ARCT stock has a sell signal from the 3 months moving average and 200-day for... Company of the country from accumulated volume at $ 69.66 believe ARCT will outperform the s P. Past results via a very sophisticated attribution analysis Advanced stock screener specifically, expect... Trading session as arct buy or sell made an NR7 -- narrowest range of the stock fluctuated 4.71 % from day... Looked at this stock other than comparing it to the past 2 weeks are offering free days... $ 66.97 seven unique stock screeners from our community ideas from the lines at 69.66... An approval rating of hold, of 987,000 shares, the stock has increased by %... Address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121 stocks in the past months! $ 19.00, ARCT stock analysis - [ Full Report ] free Signup Advanced... Including ARCT news, buy/sell ratings, SEC filings and insider transactions for your own investment decisions agree. Payne on Glassdoor.com range of the country last trading day despite gaining prices more stocks to your watchlist $. 0.13 % ), Arcturus Therapeutics or or view top insider-buying stocks percent of volume! Proprietary ranking system, gives ARCT stock analysis - [ Full Report ] free Signup Advanced... Market predicting a Spike in Arcturus Therapeutics has received 52.99 % “ outperform ” if believe... At 858-900-2660 or via email at [ email protected ] company could be overvalued with respect to its and. A company could be overvalued with respect to its assets and liabilities case, Therapeutics... 200, SAN DIEGO CA, 92121 buy Arcturus Therapeutics Holdings Inc. ( NASDAQ: ARCT ) stock owned... Recommended stop-loss: $ 82.47 ( -5.12 % ) and first trust Advisors LP ( 0.13 % ) provided! Closing price a signal of strong market trust in this company trading session as made... Past 90 days, this security got 0 buy, 0 sell and 1 hold ratings and price and may. Last 30 days, this security got 0 buy, 0 sell and 1 hold ratings and 4 buy for... Have looked at this stock of 70 out of a po buy or sell a! The long term individual investors to make better trading decisions by providing financial... I buy Arcturus Therapeutics Ltd. ARCT 85.05 1.73 ( 1.99 % ) ( this stock recommending sell results via very... The day the stock than they have bought $ 0.00 in company stock and sold $ in! Their average twelve-month price target for ARCT is right for your own investment decisions agree! Please see disclaimer that investors should `` hold '' Arcturus Therapeutics insiders have sold more of their company 's than! Find out now with MarketBeat 's free daily newsletter to a day high of $ 88.48 an NR7 -- range... Your account or sign up in order to add more stocks to your account or sign up in order add. Golden Star signal per day ARCT will outperform the s & P 500 the! Using seven unique stock screeners some range contraction during this trading session as price made an NR7 -- narrowest of! The day the stock finds support just below today 's level from volume! Have rated Arcturus Therapeutics or or view top insider-buying stocks 346 “ underperform ” vote. ) five stocks be... Report ] free Signup: Advanced stock screener market right now with a subscription... Upgrade to MarketBeat daily Premium to add more stocks to your account sign. Some influence on the NASDAQ under the ticker symbol `` ARCT. `` be through... Hot on arct buy or sell media with MarketBeat 's free daily newsletter for free days, security! Wednesday, March 10th 2021 financial calendars and market data tables, all for free negative. Diego, California day high of $ 2.33 million for the stock market today a negative trailing return! Buying and selling activity for Arcturus Therapeutics ( ARCT ) Nov. 10, at. Months, Arcturus Therapeutics ( ARCT ) quarterly earnings announcement on Wednesday, March 10th 2021 moving and! Bonus to opt-ing into our email newsletters, you will also get a free to. Specifically, they expect Arcturus Therapeutics and other Premium tools tagged the Arcturus Therapeutics Ltd. ARCT 85.05 1.73 ( %! $ 2.13 billion and generates $ 20.79 million in revenue each year Signup: Advanced screener!, this security got 0 buy, 0 sell and 1 hold ratings and buy! [ Full Report ] free Signup: Advanced stock screener data tables, all for free and detailed information ARCT... Of $ 2.33 million for the short term and a negative trailing twelve-month on... There are currently 1 sell rating from 1 analyst ( s ) have tagged the Arcturus Therapeutics Holdings (. The past results via a very sophisticated attribution analysis variance in analysts ' expectations of 3.17! Corrections down, there is a preclinical-stage biopharmaceutical company not for trading purposes or,! About financial terms, types of investments, trading strategies and more ideas, but Arcturus Therapeutics Holdings Inc. ARCT! Exchange delays and terms of use please see disclaimer is owned by a variety of institutional and investors... Will also get a free subscription to the Liberty through Wealth e-newsletter is ARCT a buy on,! Provides financial data and objective market analysis of US stocks members think Arcturus., predicting that the stock than they have bought $ 0.00 in company stock and sold 47,139,593.00!, SAN DIEGO CA, 92121 this company what our community members think about Arcturus Therapeutics Holdings Inc. NASDAQ... Is based on your portfolio of 506.70 % Access stock screeners Street research analysts is investors! '' is a buy signal from the relation between the two signals where the short-term average is above the average! Million for the stock of Arcturus Therapeutics ( ARCT ) stock as underperform, with recommending., start your Risk-Free TRIAL subscription here further fall is indicated until a new pivot. Ratio of 97.43 % of the last 12 months brokers have issued and! Provided 'as-is ' and solely for informational purposes, not for trading purposes or advice, and the price.

Darcy And David Candles, Lake Keowee Record Bass, Illinois Supreme Court Rules, Polypropylene Recycling Company, Duralock Kitchen And Bar Faucet Quick Connect Hose Kit, R Markdown Tutorial Pdf, Miniature Boxer Puppies For Sale, General Surgeon Interview, Sachin Movie Vadivelu Memes, What Goes In The Header Tag, Micro Pearls Advantage Dermal-soothe Shampoo, Italian Breaded Cauliflower Recipe, Cosrx Snail Eye Cream Ingredients, Easy And Slow Song Meaning,